BioCryst Pharmaceuticals Inc (BCRX)
BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.
BCRX SEC Filing Email Alerts Service
Company Name: |
BioCryst Pharmaceuticals Inc |
Website: |
www.biocryst.com |
Sector: |
Biotechnology |
Number of ETFs Holding BCRX: |
28 |
Total Market Value Held by ETFs: |
$159.90M |
Total Market Capitalization: |
$880.00M |
% of Market Cap. Held by ETFs: |
18.17% |
|
|
May 1, 2024 8:18 PM Eastern
Strong Buy (3.50 out of 4)
59th percentile
|
|